SYGNIS plans to acquire profitable proteomics player
Combined 2016 pro-forma revenues to exceed EUR 5 million
09-May-2016 -
SYGNIS AG resolved, with the approval of the Supervisory Board, to acquire Expedeon Holdings Ltd., a privately held UK proteomics companywith sales offices in the U.S., UK and Singapore. Expedeon develops, manufactures and commercializes proteomics reagents and tools, marketed worldwide by ...
acquisitions
proteomics
shares